The University of Florida has prepared and tested PPARγ agonists reported to be useful for the treatment of diabetes, hyperparathyroidism, metabolic syndrome, multiple myeloma, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), obesity, osteoporosis and Paget disease, among others.